Source: Annual Congress 2010 - Basic mechanisms in malignant pleural disease biology
Disease area: Thoracic oncology



Rating:

Share or cite this content

Citations should be made in the following way:
S. Miyoshi, H. Hamada, N. Hamaguchi, S. Hamaguchi, A. Kato, K. Irifune, R. Ito, J. Higaki (Toon, Japan). Inhibition of phosphatidylinositol 3-kinase and mitogen-activated protein kinase kinase prevents malignant pleural mesothelioma cell growth. Eur Respir J 2010; 36: Suppl. 54, 3856

Member's Comments

No comment yet.

Related content which might interest you: Constitutive phosphorylation of p38 mitogen activated protein kinase controls proliferation of mesothelioma cells Source: Eur Respir J 2005; 26: Suppl. 49, 225s Year: 2005 The inhibitory effect of PI3k inhibitor and MEK inhibitor on malignant pleural mesothelioma cell growth Source: Annual Congress 2009 - Pleural and mediastinal diseases Year: 2009 Increased phosphorylated p38 mitogen-activated protein kinase in COPD lungs Source: Eur Respir J 2013; 42: 28-41 Year: 2013 Activation of second messenger pathways in alveolar macrophages by endotoxin Source: Eur Respir J 2002; 20: 210-222 Year: 2002 Antitumor activity of MEK and PI3K inhibitors in malignant pleural mesothelioma Source: Annual Congress 2011 - Treatment options and tumour biology of malignant pleural mesothelioma Year: 2011 Transmission of muscarinic receptor mediated proliferative effects in human lung fibroblasts involves ERK-MAP kinase, but not PI-3 kinase and Rho-kinase pathway Source: Annual Congress 2007 - Miscellaneous pulmonary pharmacology Year: 2007 Role of p38 mitogen-activated protein kinase in trauma/hemorrhage and subsequent peumococcal pneumonia Source: Annual Congress 2010 - Aetiology of lower respiratory tract infections and treatment in special situations Year: 2010 LATE-BREAKING ABSTRACT: Evaluation of an oral p38 mitogen activated protein kinase (MAPK inhibitor) SB-681323 in COPD Source: Annual Congress 2009 - COPD: from biomarker profiling to clinical assessment Year: 2009 LSC 2010 Abstract: Mesothelioma cell proliferation is controlled by mitogen activated protein kinase Erk1/2 and p38 and subsequent C/EBP-β activation Source: Annual Congress 2010 - Basic mechanisms in malignant pleural disease biology Year: 2010 Effect of fudosteine on mucin production Source: Eur Respir J 2008; 32: 1195-1202 Year: 2008 Phosphoinositide 3-kinase ? inhibitor suppresses interleukin-17 expression in a murine asthma model Source: Eur Respir J 2010; 36: 1448-1459 Year: 2010 The effects of oral p38 mitogen activated protein kinase (MAPK) inhibitor SB-681323 on blood biomarkers in COPD Source: Annual Congress 2008 - Novel treatments for respiratory disease Year: 2008 Inhibition of p38 MAPK-dependent bronchial contraction after ozone by corticosteroids Source: Eur Respir J 2011; 37: 933-942 Year: 2011 Ventilation-induced activation of the mitogen-activated protein kinase pathway Source: Eur Respir J 2002; 20: 946-956 Year: 2002 Effect of smoking on MAP kinase-induced modulation of IL-8 in human alveolar macrophages Source: Eur Respir J 2004; 23: 805-812 Year: 2004 Regulation of cytokine- and phorbol ester-mediated interleukin (IL)-8 expression in the absence or presence of pyocyanin in human bronchial epithelial cell line: roles of protein kinase C and mitogen-activated protein kinases Source: Eur Respir J 2005; 26: Suppl. 49, 99s Year: 2005 Effects of glucocorticoids on activation of extracellular signal-regulated kinases (ERK) in human pulmonary endothelial cells Source: Eur Respir J 2001; 18: Suppl. 33, 160s Year: 2001 A temporal effect of EGFR tyrosine kinase inhibitor in lymphoepithelioma-like carcinoma of lung Source: Annual Congress 2012 - Instructive clinical aspects of thoracic oncology Year: 2012